$NVO News

Novo Nordisk Gets European Commission Extension To Marketing Authorisation For Wegovy In EU To Add An Oral Formulation For Weight Management

Novo Nordisk To Unveil Data Showing Semaglutide Tackles The Liver Disease Crisis Affecting About 1 In 3 People Living With Overweight And Obesity Worldwide

Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today

Novo Nordisk Highlights New Wegovy Pill Data

Novo Nordisk: Why A P/E Of 13 Is A Value Trap, Not A Bargain

Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction

Novo Nordisk Says Wegovy Showed An Average 22.6% Weight Loss For Premenopausal Women With Obesity, With More Than 41% Achieving 25% Or More Weight Loss

Cellular Intelligence To Acquire Novo Nordisk's STEM-PD Parkinson's Cell Therapy Program; No Financial Terms Disclosed

Novo Nordisk: Flipping The Script

Novo Nordisk: Misread Q1 Earnings, Mispriced Stock

Novo Nordisk A/S (NOVO:CA) Q1 2026 Earnings Call Transcript

'Novo Sees Generic Ozempic Delayed in China Until Next Year' - Bloomberg

Wegovy Pill Debut 'Fattens' Novo Nordisk's Profit Outlook

Novo Nordisk Raises FY2026 Sales Guidance from $40.463B-$44.317B to $42.389B-$46.243B vs $45.440B Est

Novo Nordisk Q1 Adj. EPS $1.04 Beats $0.87 Estimate, Sales $15.173B Beat $11.130B Estimate

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 15 Years

Novo Nordisk: My Q1 Preview And Why I'm Doubling Down

Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List; Finds No Clinical Need For Bulk Compounding Of These Drugs

Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview)